Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allogene Therapeutics, Inc. (Nasdaq: ALLO) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Allogene files periodic reports and current reports that describe its AlloCAR T pipeline, financial condition, and key risks.
Among the most relevant filings for ALLO are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss clinical programs such as cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma, ALLO-329 in autoimmune disease, and ALLO-316 in renal cell carcinoma. These reports also include detailed risk factor sections covering topics like gene-editing technology, reliance on licensed TALEN-based platforms, and intellectual property disputes referenced in company disclosures.
Allogene also submits numerous current reports on Form 8-K to describe material events. Recent 8-K filings have furnished quarterly financial results, outlined changes to the ALPHA3 trial’s lymphodepletion regimen following safety review, and described third-party patent litigation involving Cellectis’s TALEN technology on which Allogene relies. Other filings document matters such as annual meeting voting results and the continued listing of ALLO common stock on The Nasdaq Stock Market LLC.
On Stock Titan, investors can use AI-powered tools to review these filings, surface key points, and understand how disclosures about clinical trial design, safety findings, intellectual property, and governance may relate to ALLO stock. The filings page is a central resource for tracking Allogene’s regulatory history, financial reporting, and formal statements about its allogeneic CAR T development strategy.
Frazier-affiliated investors report shared ownership stakes in Allogene Therapeutics common stock. Frazier Life Sciences Public Fund, L.P. holds 16,205,306 shares (4.7%). Related Frazier funds hold additional positions: 306,906 shares (0.1%), 722,956 shares (0.2%), and 1,561,500 shares (0.5%) in separate partnerships. The percent calculations reference 243,777,920 shares outstanding as of March 10, 2026 and incorporate 100,200,000 shares sold by the issuer on April 16, 2026.
Allogene Therapeutics SVP of Finance Annie Yoshiyama reported a small share sale mainly for tax purposes. She sold 9,586 shares of common stock in an open-market transaction to cover tax withholding obligations tied to the vesting of restricted stock units under a mandated “sell to cover” arrangement, rather than a discretionary trade. The weighted average sale price ranged from $2.31 to $2.33 per share. After this transaction, she directly holds 124,517 Allogene shares, which include 3,781 shares acquired on March 15, 2026 through an employee stock purchase program.
Allogene Therapeutics submitted a Form 144 reporting the vesting of 9,586 shares of Common Stock from a restricted stock unit award. The vesting date shown is 04/20/2026 and the Form 144 filing line shows 04/21/2026.
Allogene Therapeutics is soliciting proxies for its virtual 2026 Annual Meeting on June 18, 2026 at 8:00 a.m. Pacific Time. Stockholders of record as of April 20, 2026 may vote on: election of three directors, advisory approval of executive compensation and frequency, an amendment to increase authorized common stock from 400,000,000 to 800,000,000 shares, and ratification of Ernst & Young LLP as auditor. The Board recommends FOR all proposals. The Board will reduce its size to ten members effective at the meeting and did not renominate Todd Sisitsky as part of planned succession and refreshment.
Allogene Therapeutics, Inc. is raising capital through an underwritten public offering of 87,500,000 shares of common stock at $2.00 per share, for expected gross proceeds of $175 million before fees and expenses. The company granted underwriters a 30-day option to buy up to 13,125,000 additional shares at the same public price, less discounts and commissions. Allogene plans to use the net proceeds for general corporate purposes, including clinical trial, research and development, general and administrative costs, and capital expenditures. The offering is being made under an effective shelf registration on Form S-3 and is expected to close around April 16, 2026, subject to customary conditions.
Allogene Therapeutics, Inc. is offering 87,500,000 shares of its common stock at a public offering price of $2.00 per share by prospectus supplement dated April 14, 2026. The underwriting agreement shows proceeds, before expenses, to Allogene of $164,500,000. The underwriters have a 30‑day option to purchase up to an additional 13,125,000 shares at the public price less underwriting discounts. The offering assumes delivery in New York on or about April 16, 2026. The number of shares outstanding immediately after this offering is based on 229,413,523 shares outstanding as of December 31, 2025.
Allogene Therapeutics is offering $175,000,000 of common stock. The prospectus supplement registers an offering of common stock with a 30-day underwriter option to purchase an additional $26,250,000 of shares. The offering references a recent market price of $2.72 per share (last reported April 10, 2026).
Separately, Allogene reported interim futility analysis data from the randomized Phase 2 ALPHA3 trial in 1L consolidation LBCL: among the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm were MRD negative at last assessment versus 16.7% (2/12) in observation, an absolute difference of 41.6%. Safety signals in this cohort showed no CRS, ICANS or GvHD events of special interest. The company expects ~220 total patients, interim EFS analysis in mid-2027 and primary EFS analysis in mid-2028.
Allogene Therapeutics is offering $175,000,000 of common stock. The prospectus supplement registers an offering of common stock with a 30-day underwriter option to purchase an additional $26,250,000 of shares. The offering references a recent market price of $2.72 per share (last reported April 10, 2026).
Separately, Allogene reported interim futility analysis data from the randomized Phase 2 ALPHA3 trial in 1L consolidation LBCL: among the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm were MRD negative at last assessment versus 16.7% (2/12) in observation, an absolute difference of 41.6%. Safety signals in this cohort showed no CRS, ICANS or GvHD events of special interest. The company expects ~220 total patients, interim EFS analysis in mid-2027 and primary EFS analysis in mid-2028.
Allogene Therapeutics, Inc. announced the commencement of a proposed underwritten public offering of its common stock. In connection with this new offering, the company has suspended sales of common stock under its existing at-the-market program conducted through a Sales Agreement with TD Securities (U.S.A.) LLC.
The company stated it will not sell shares under that Sales Agreement again unless and until it files a new prospectus or prospectus supplement with the SEC. Any sales related to the proposed offering will be made only through a written prospectus that meets Securities Act requirements.
Allogene Therapeutics, Inc. announced the commencement of a proposed underwritten public offering of its common stock. In connection with this new offering, the company has suspended sales of common stock under its existing at-the-market program conducted through a Sales Agreement with TD Securities (U.S.A.) LLC.
The company stated it will not sell shares under that Sales Agreement again unless and until it files a new prospectus or prospectus supplement with the SEC. Any sales related to the proposed offering will be made only through a written prospectus that meets Securities Act requirements.
Allogene Therapeutics reported interim results from its pivotal Phase 2 ALPHA3 trial of its allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. In the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm achieved minimal residual disease (MRD) negativity versus 16.7% (2/12) with observation, a 41.6 percentage-point difference in MRD clearance.
Plasma ctDNA levels at Day 45 fell by a median 97.7% from baseline with cema-cel, while the observation arm showed a 26.6% median increase. Cema-cel was generally well tolerated, with no treatment-related serious adverse events, and no reported cytokine release syndrome, ICANS, or graft-versus-host disease. Ten of 12 treated patients were managed fully as outpatients.
The ALPHA3 trial is enrolling about 220 high-risk patients across more than 60 sites and is powered to detect a 50% reduction in event-free survival risk. Allogene expects an interim EFS analysis in mid-2027 and a primary EFS analysis in mid-2028, which, if positive, could support a Biologics License Application for cema-cel.
Allogene Therapeutics reported interim results from its pivotal Phase 2 ALPHA3 trial of its allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. In the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm achieved minimal residual disease (MRD) negativity versus 16.7% (2/12) with observation, a 41.6 percentage-point difference in MRD clearance.
Plasma ctDNA levels at Day 45 fell by a median 97.7% from baseline with cema-cel, while the observation arm showed a 26.6% median increase. Cema-cel was generally well tolerated, with no treatment-related serious adverse events, and no reported cytokine release syndrome, ICANS, or graft-versus-host disease. Ten of 12 treated patients were managed fully as outpatients.
The ALPHA3 trial is enrolling about 220 high-risk patients across more than 60 sites and is powered to detect a 50% reduction in event-free survival risk. Allogene expects an interim EFS analysis in mid-2027 and a primary EFS analysis in mid-2028, which, if positive, could support a Biologics License Application for cema-cel.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported a small sale of 2,867 shares of Common Stock at $2.50 per share. The company states this transaction was executed solely to cover tax withholding obligations tied to vesting restricted stock units under its equity incentive plan.
Following the sale, Beneski directly holds 195,338 shares of Allogene Therapeutics common stock. The filing explains the sale was a mandatory “sell to cover” transaction chosen by the company’s plan and is not a discretionary trade by the executive.